1. Kyoto University Research Information Repository
  2. 440　iPS細胞研究所
  3. 学術雑誌掲載論文等
このアイテムのアクセス数: 580

    このアイテムの引用には次の識別子を使用してください: http://hdl.handle.net/2433/252792
このアイテムのファイル:
ファイル 記述 サイズフォーマット 
s41467-020-17165-w.pdf3.36 MBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド値言語
dc.contributor.authorDoi, Daisukeen
dc.contributor.authorMagotani, Hiroakien
dc.contributor.authorKikuchi, Tetsuhiroen
dc.contributor.authorIkeda, Megumien
dc.contributor.authorHiramatsu, Satoeen
dc.contributor.authorYoshida, Kenjien
dc.contributor.authorAmano, Naokien
dc.contributor.authorNomura, Masakien
dc.contributor.authorUmekage, Masafumien
dc.contributor.authorMorizane, Asukaen
dc.contributor.authorTakahashi, Junen
dc.contributor.alternative土井, 大輔ja
dc.contributor.alternative孫谷, 弘明ja
dc.contributor.alternative菊地, 哲広ja
dc.contributor.alternative池田, 愛ja
dc.contributor.alternative平松, 里恵ja
dc.contributor.alternative吉田, 賢司ja
dc.contributor.alternative天野, 直己ja
dc.contributor.alternative野村, 真樹ja
dc.contributor.alternative梅景, 雅史ja
dc.contributor.alternative森実, 飛鳥ja
dc.contributor.alternative髙橋, 淳ja
dc.date.accessioned2020-07-21T01:14:56Z-
dc.date.available2020-07-21T01:14:56Z-
dc.date.issued2020-07-06-
dc.identifier.issn2041-1723-
dc.identifier.urihttp://hdl.handle.net/2433/252792-
dc.description臨床用iPS細胞を用いたパーキンソン病治療の非臨床研究を実施 --ヒトiPS細胞由来のドパミン神経前駆細胞の安全性と有効性を確認--. 京都大学プレスリリース. 2020-07-20.ja
dc.description.abstractInduced pluripotent stem cell (iPSC)-derived dopaminergic (DA) neurons are an expected source for cell-based therapies for Parkinson’s disease (PD). The regulatory criteria for the clinical application of these therapies, however, have not been established. Here we show the results of our pre-clinical study, in which we evaluate the safety and efficacy of dopaminergic progenitors (DAPs) derived from a clinical-grade human iPSC line. We confirm the characteristics of DAPs by in vitro analyses. We also verify that the DAP population include no residual undifferentiated iPSCs or early neural stem cells and have no genetic aberration in cancer-related genes. Furthermore, in vivo studies using immunodeficient mice reveal no tumorigenicity or toxicity of the cells. When the DAPs are transplanted into the striatum of 6-OHDA-lesioned rats, the animals show behavioral improvement. Based on these results, we started a clinical trial to treat PD patients in 2018.en
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherSpringer Natureen
dc.rights© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.en
dc.subjectInduced pluripotent stem cellsen
dc.subjectParkinson's diseaseen
dc.subjectRegenerative medicineen
dc.subjectStem-cell differentiationen
dc.titlePre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson’s diseaseen
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleNature Communicationsen
dc.identifier.volume11-
dc.relation.doi10.1038/s41467-020-17165-w-
dc.textversionpublisher-
dc.identifier.artnum3369-
dc.identifier.pmid32632153-
dc.relation.urlhttps://www.kyoto-u.ac.jp/ja/research-news/2020-07-20-
dcterms.accessRightsopen access-
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。